Novo Nordisk A/S (NVO) Net Profit Margin: 37.14%
Is Novo Nordisk A/S’s net profit margin high or low?
Novo Nordisk A/S's net profit margin of 37.14% is 10% above its 5-year average of 33.74%, near the high end of its 5-year range (31.38%–37.14%).
As of Saturday, June 20, 2026. 9.36% above its 12-month average of 33.96%.
NVO Net Profit Margin Chart
NVO Average Net Profit Margin Chart
NVO Current vs Average Net Profit Margin Chart
NVO Net Profit Margin Metrics
NET PROFIT MARGIN
37.14%
NET PROFIT MARGIN AVG TTM
33.96%
NET PROFIT MARGIN AVG 3Y
33.83%
NET PROFIT MARGIN AVG 5Y
33.74%
NET PROFIT MARGIN AVG 10Y
33.57%
NET PROFIT MARGIN AVG 15Y
32.16%
NET PROFIT MARGIN AVG 20Y
28.71%
CURRENT VS TTM AVG
+9.36%
CURRENT VS 3Y AVG
+9.78%
CURRENT VS 5Y AVG
+10.08%
CURRENT VS 10Y AVG
+10.63%
CURRENT VS 15Y AVG
+15.47%
CURRENT VS 20Y AVG
+29.38%
NVO Competitors' Net Profit Margin
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Novo Nordisk A/S (NVO) | $191.93B | 37.14% | 33.96% | 33.83% | 33.74% |
| Amgen Inc. (AMGN)vs › | $182.21B | 20.95% | 16.61% | 20.49% | 22.20% |
| Thermo Fisher Scientific Inc. (TMO)vs › | $172.66B | 15.18% | 14.95% | 14.84% | 16.47% |
| Abbott Laboratories (ABT)vs › | $153.94B | 13.91% | 23.34% | 19.20% | 17.71% |
| Gilead Sciences, Inc. (GILD)vs › | $153.66B | 30.99% | 15.29% | 17.07% | 15.27% |
| Intuitive Surgical, Inc. (ISRG)vs › | $144.07B | 28.15% | 28.09% | 25.67% | 26.14% |
| Pfizer Inc. (PFE)vs › | $143.74B | 11.83% | 12.51% | 14.97% | 18.18% |
| CVS Health Corporation (CVS)vs › | $125.45B | 0.72% | 0.84% | 1.34% | 1.79% |
| Danaher Corporation (DHR)vs › | $125.40B | 14.89% | 15.52% | 19.51% | 19.37% |
| Stryker Corporation (SYK)vs › | $118.00B | 13.21% | 13.09% | 13.60% | 12.87% |
Margin Comparison
Operating Margin
45.2%
Net Profit Margin
37.1%
Novo Nordisk A/S Net Profit Margin Formula & Definition
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Novo Nordisk A/S Net Profit Margin FAQ
- What is the net profit margin for Novo Nordisk A/S (NVO)?
- The net profit margin for NVO stock is 37.14%.
- Is Novo Nordisk A/S's net profit margin high or low?
- Novo Nordisk A/S's net profit margin of 37.14% is 10% above its 5-year average of 33.74%, near the high end of its 5-year range (31.38%–37.14%).
- What is the TTM average net profit margin for Novo Nordisk A/S (NVO)?
- The TTM average net profit margin for NVO stock is 33.96%.
- What is the 3Y average net profit margin for Novo Nordisk A/S (NVO)?
- The 3Y average net profit margin for NVO stock is 33.83%.
- What is the 5Y average net profit margin for Novo Nordisk A/S (NVO)?
- The 5Y average net profit margin for NVO stock is 33.74%.
- What is the 10Y average net profit margin for Novo Nordisk A/S (NVO)?
- The 10Y average net profit margin for NVO stock is 33.57%.
- What is the 15Y average net profit margin for Novo Nordisk A/S (NVO)?
- The 15Y average net profit margin for NVO stock is 32.16%.
- What is the 20Y average net profit margin for Novo Nordisk A/S (NVO)?
- The 20Y average net profit margin for NVO stock is 28.71%.
Novo Nordisk A/S Net Profit Margin History
| DATE | NET PROFIT MARGIN |
|---|---|
| 2025-12-31 | 33.14% |
| 2024-12-31 | 34.78% |
| 2023-12-31 | 36.03% |
| 2022-12-31 | 31.38% |
| 2021-12-31 | 33.92% |
| 2020-12-31 | 33.19% |
| 2019-12-31 | 31.92% |
| 2018-12-31 | 34.54% |
| 2017-12-31 | 34.14% |
| 2016-12-31 | 33.93% |
| 2015-12-31 | 32.30% |
| 2014-12-31 | 29.82% |
| 2013-12-31 | 30.13% |
| 2012-12-31 | 27.47% |
| 2011-12-31 | 25.77% |
| 2010-12-31 | 23.70% |
| 2009-12-31 | 21.08% |
| 2008-12-31 | 21.17% |
| 2007-12-31 | 20.38% |
| 2006-12-31 | 16.65% |
| 2005-12-31 | 17.37% |
| 2004-12-31 | 17.27% |
| 2003-12-31 | 18.31% |
| 2002-12-31 | 16.26% |
| 2001-12-31 | 16.24% |
| 2000-12-31 | 14.84% |
| 1999-12-31 | 14.70% |
| 1998-12-31 | 17.69% |
| 1997-12-31 | 13.07% |
| 1996-12-31 | 12.09% |
Related Metrics
About Novo Nordisk A/S
Novo Nordisk A/S is a global pharmaceutical firm dedicated to the investigation, creation, manufacturing, and distribution of medicinal products across a vast international footprint. Its market presence extends throughout Europe, the Middle East, Africa, various parts of Asia (including Mainland China, Hong Kong, and Taiwan), and North America. The company's operations are structured into two principal business units: Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity Care division delivers therapies for diabetes, obesity, cardiovascular ailments, and other emerging therapeutic areas. Meanwhile, the Rare Disease division concentrates on providing treatments for rare blood disorders, uncommon endocrine conditions, and hormone replacement solutions. In addition to its core pharmaceutical offerings, Novo Nordisk produces specialized medical equipment such as insulin pens, growth hormone pens, and injection needles. It also pioneers smart digital solutions for diabetes management, including advanced insulin pens and the Dose Check application, designed to guide insulin dosage. The company engages in strategic alliances, notably a partnership with UNICEF to combat childhood obesity and a collaboration with Valo Health, Inc. to discover and advance novel drug pipelines in the cardiometabolic space. Founded in 1923, Novo Nordisk A/S is headquartered in Bagsvaerd, Denmark.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Maziar Mike Doustdar